ERC-CG-2013-LS7
ERC-CG-2013-LS7
Programme: H2020
15 projects · €29,578,555 total EU contribution (project-level) · 20 participating organizations · 12 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€29,578,555
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (7)
- CH (2)
- SE (2)
- BE (1)
- CA (1)
- DK (1)
- Spain (1)
- IL (1)
- Netherlands (1)
- NO (1)
- NZ (1)
- UK (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- UMIL2 projects · IT
- ETH Zürich1 projects · CH
- NORWEGIAN INSTITUTE OF PUBLIC HEALTH NIPH1 projects · NO
- INGM1 projects · IT
- FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE1 projects · ES
- ISTITUTO EUROPEO DI ONCOLOGIA SRL1 projects · IT
- KI1 projects · SE
- UCPH1 projects · DK
- KTH1 projects · SE
- OSR1 projects · IT
- SWISS TPH SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE1 projects · CH
- TAU1 projects · IL
Projects
Page 2 of 2
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
G-quadruplexes in the HIV-1 genome: novel targets for the development of selective antiviral drugs HIV LTR G-4 · 615879 | FP7 | €1,989,471 | €1,989,471 | Details |
Genetics-driven targeted therapy of Hairy Cell Leukemia Hairy Cell Leukemia · 617471 | FP7 | €2,000,000 | €2,000,000 | Details |
Long non-coding RNAs of tumor infiltrating lymphocytes as novel anti-cancer therapeutic targets FIGHT-CANCER · 617978 | FP7 | €1,998,000 | €1,998,000 | Details |
Targeting cancer using evolutionary refined pathogen derived antigens MalOnco · 615905 | FP7 | €1,998,800 | €1,998,800 | Details |
Uncovering the molecular and cellular mechanism of tumor dormancy for the rational design of theranostic nanomedicines POLYDORM · 617445 | FP7 | €2,255,920 | €2,255,920 | Details |